Research programme - secretory immunoglobulin A - BioSavita

Drug Profile

Research programme - secretory immunoglobulin A - BioSavita

Alternative Names: Immunoglobulin A - BioSavita; Secretory IgA - BioSavita; Secretory immunoglobulin A - BioSavita

Latest Information Update: 16 Jul 2016

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator BioSavita
  • Class Antibodies
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • Available For Licensing Yes

Highest Development Phases

  • No development reported Clostridium infections

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for research development in Clostridium-infections in USA (Parenteral)
  • 09 May 2013 BioSavita receives Qualifying Therapeutic Discovery Project grant from the Internal Revenue Service for secretory immunoglobulin A development in Clostridium infections
  • 06 May 2013 Research programme - secretory immunoglobulin A - BioSavita is available for licensing as of 06 May 2013. http://biosavita.com/
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top